Russia’s sovereign wealth fund The Russian Direct Investment Fund (RDIF), announced the production of a first batch of 200 litres of cell culture fluid biomass in partnership with the Russian-Japanese company EMG. This will enable EMG to produce up to one million high-quality rapid tests for the detection of COVID-19.
The Institute of Bioorganic Chemistry and Combiotech is manufacturing biomass to produce DNA polymerase – an enzyme which is one of the key components of the Russian-Japanese express testing system. Recently RDIF has invested in the production and distribution of the Russian-Japanese diagnostic system EMG – Evotech-Mirai Genomics, which is one of the world’s most accurate and fastest systems for the detection of coronavirus.
In March 2020, The Russian Direct Investment Fund (RDIF), announced its supports to MD Medical Group (RDIF portfolio company) to start treating patients with pneumonia symptoms, including patients with coronavirus symptoms, at its clinical hospital Lapino.
Also in March 2020, The Russian Direct Investment Fund (RDIF), RUIE (the Russian Union of Industrialists and Entrepreneurs), Yandex and Mail.ru Group announced the creation of an alliance against coronavirus (COVID-19).
Moscow based Russian Direct Investment Fund (RDIF) is Russia’s sovereign wealth fund. RDIF was founded in 2011 to make equity co-investments, primarily in Russia, alongside reputable international financial and strategic investors. It has implemented almost 70 projects in partnership with foreign entity. RDIFs portfolio of companies employs approximately 800,000 people and generates revenues which equate to over 6% of Russias GDP.